At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
Vinorelbine +4 moredrug
Likely dose
Vinorelbine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial With Metronomic Oral Vinorelbine and Tri-weekly Cisplatin as Induction Therapy and Subsequent Concomitantly With Radiotherapy (RT) in Patients With Lung Cancer (NSCLC) Locally Advanced Unresectable
In Brief
A Phase 2 clinical trial evaluating Vinorelbine, Cisplatin, and 1 other intervention for Lung Cancer. Completed, enrolled 68 participants across 18 sites.
Detailed Summary
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy and subsequent concomitantly with radiotherapy (RT) in patients with lung cancer (NSCLC) locally advanced unresectable
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionApr 2019
Study CompletionDec 2019
TodayJul 2026
First PostedMar 16, 2016
Enrollment StartApr 15, 2016
Primary CompletionApr 15, 2019
Study CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 10.3 years ago
Interventions
Vinorelbinedrug
Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
Cisplatindrug
Cycle 1 and 2 day 1, 80 mg/m2
Vinorelbinedrug
Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
Cisplatindrug
Cycle 3 and 4 day 1, 80 mg/m2
Radiotherapyradiation
concomitant therapy during cycles 3 and 4. Total dose: 66Gy